{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:07Z","timestamp":1787022187638,"version":"build-2736575974"},"reference-count":85,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPSG-2024-01-02406"],"award-info":[{"award-number":["IIRPSG-2024-01-02406"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Breast cancer is one of the most prevalent cancers worldwide, ranked as the second most diagnosed cancer and the fourth leading cause of cancer-related deaths. Despite the availability of FDA-approved therapies, limitations such as drug resistance and off-target effects highlight the need for novel, multitargeted therapeutic agents. In this study, we aimed to identify and design an in-silico promising multitarget drug for breast cancer by simultaneously targeting three critical proteins: Glucocorticoid Receptor, Estrogen Receptor-alpha (ER-alpha), and Cyclin-Dependent Kinase 2 (CDK2). FDA-approved drugs corresponding to these targets were initially subjected to multitarget molecular docking to evaluate their binding affinities. Based on this screening, the 15 highest-ranking ligands were selected and underwent molecular enumeration, resulting in the generation of 14,750 novel derivative compounds. The re-docking identified 1-((R)-2,3-dihydroxypropyl) \u22123-(3-((R)-1\u20135-methyl-1H-pyrrolo [2,3-b]pyridin-3-yl)ethyl)phenyl) urea (DdpMPyPEPhU) (Patent No. 202024101028.0) as a promising multitarget candidate. The compound exhibited enhanced binding pocket engagement through numerous stabilising interactions, including hydrogen bonds, \u03c0-\u03c0 stacking, and \u03c0-cation interactions, with high docking scores (\u201314.869 to \u20134.57 kcal\/mol) and favourable Molecular Mechanics Generalised Born Surface Area (MM-GBSA) energies (\u201372.32 to \u201311.97 kcal\/mol). Comparative docking and pharmacokinetic analyses with standard drugs Lapatinib and Tamoxifen indicated better drug-like properties and pharmacokinetic advantages for DdpMPyPEPhU. Additional validation using Density Functional Theory (DFT) optimisation, 5 ns WaterMap analysis, and 250 ns molecular dynamics simulations under neutralised conditions confirmed structural stability and strong intermolecular interactions, supported by binding free energy calculations. Overall, our computational findings suggest that DdpMPyPEPhU is a promising therapeutic candidate for breast cancer, providing a rational basis for further experimental evaluation.<\/jats:p>","DOI":"10.1371\/journal.pone.0344028","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:33:46Z","timestamp":1774287226000},"page":"e0344028","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-2830","authenticated-orcid":true,"given":"Shaban","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagmi","family":"Bano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahis","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod Kumar","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-6828","authenticated-orcid":true,"given":"Khalid","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"pone.0344028.ref001","doi-asserted-by":"crossref","unstructured":"Shonkwiler RW, et al. Cancer: A Disease of the DNA, Mathematical Biology: An Introduction with Maple and Matlab. 2009:399\u2013416.","DOI":"10.1007\/978-0-387-70984-0_12"},{"key":"pone.0344028.ref002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/9781118785621.ch2","article-title":"Cancer Basics","volume-title":"Cancer Chemotherapy for the Veterinary Health Team","author":"K Crump","year":"2011"},{"key":"pone.0344028.ref003","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"pone.0344028.ref004","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","author":"J Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"11","key":"pone.0344028.ref005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cancers9110155","article-title":"Current and Prospective Protein Biomarkers of Lung Cancer","volume":"9","author":"TN Zamay","year":"2017","journal-title":"Cancers (Basel)"},{"key":"pone.0344028.ref006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-981-19-8249-1_13","volume-title":"Therapeutic protein-based vaccines, Protein-based therapeutics","author":"S Ahmad","year":"2023"},{"issue":"3","key":"pone.0344028.ref007","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0022-5193(71)90020-8","article-title":"Differentiation of malignant to benign cells","volume":"31","author":"S Kauffman","year":"1971","journal-title":"J Theor Biol"},{"issue":"1","key":"pone.0344028.ref008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers16040687","article-title":"Radical resection of malignant tumours of major salivary glands: is this possible?","volume":"16","author":"G Cant\u00f9","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"pone.0344028.ref009","doi-asserted-by":"crossref","first-page":"16545","DOI":"10.1038\/s41598-023-43789-1","article-title":"In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma","volume":"13","author":"A Sahu","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0344028.ref010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/0929867330666230309143711","article-title":"Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis","volume":"31","author":"AA Shah","year":"2024","journal-title":"Curr Med Chem"},{"key":"pone.0344028.ref011","doi-asserted-by":"crossref","first-page":"20503121211034366","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: Current perspectives","volume":"9","author":"DT Debela","year":"2021","journal-title":"SAGE Open Med"},{"issue":"3","key":"pone.0344028.ref012","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/138945006776054942","article-title":"Biodiversity as a source of anticancer drugs","volume":"7","author":"G Tan","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"3","key":"pone.0344028.ref013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"AG Waks","year":"2019","journal-title":"JAMA"},{"key":"pone.0344028.ref014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0090-6980(02)00029-1","article-title":"Distinct functions of COX-1 and COX-2","author":"I Morita","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"5","key":"pone.0344028.ref015","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/07391102.2023.2209673","article-title":"Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: an optimisation followed multi-simulation and in-vitro study","volume":"42","author":"S Ahmad","year":"2024","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"pone.0344028.ref016","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/07391102.2023.2291174","article-title":"Investigating the multitargeted anti-diabetic potential of cucurbitane-type triterpenoid from Momordica charantia: an LC-MS, docking-based MM\\GBSA and MD simulation study","volume":"43","author":"SO Famuyiwa","year":"2025","journal-title":"J Biomol Struct Dyn"},{"issue":"11","key":"pone.0344028.ref017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12032-023-02203-6","article-title":"Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\\GBSA and MD simulation study","volume":"40","author":"MA Alshehri","year":"2023","journal-title":"Med Oncol"},{"issue":"7","key":"pone.0344028.ref018","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"AK Shiau","year":"1998","journal-title":"Cell"},{"issue":"1","key":"pone.0344028.ref019","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/jm990401t","article-title":"Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase","volume":"43","author":"L Shewchuk","year":"2000","journal-title":"J Med Chem"},{"issue":"25","key":"pone.0344028.ref020","doi-asserted-by":"crossref","first-page":"22748","DOI":"10.1074\/jbc.M212711200","article-title":"The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism","volume":"278","author":"B Kauppi","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"pone.0344028.ref021","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"S Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"pone.0344028.ref022","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"CK Osborne","year":"2011","journal-title":"Annu Rev Med"},{"issue":"3","key":"pone.0344028.ref023","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"KH Vousden","year":"2009","journal-title":"Cell"},{"issue":"8","key":"pone.0344028.ref024","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.2005.10.036","article-title":"Estrogen-receptor biology: continuing progress and therapeutic implications","volume":"23","author":"CK Osborne","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0344028.ref025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"S Ali","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"pone.0344028.ref026","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"EA Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"pone.0344028.ref027","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"P Hydbring","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"36","key":"pone.0344028.ref028","doi-asserted-by":"crossref","first-page":"30117","DOI":"10.1074\/jbc.M112.367326","article-title":"p53, a target of estrogen receptor (ER) \u03b1, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells","volume":"287","author":"CE Berger","year":"2012","journal-title":"J Biol Chem"},{"issue":"19","key":"pone.0344028.ref029","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.3390\/ijms221910260","article-title":"Growth Factors, PI3K\/AKT\/mTOR and MAPK Signaling Pathways in Colorectal Cmmpancer Pathogenesis: Where Are We Now?","volume":"22","author":"C Stefani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"pone.0344028.ref030","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"CJ Sherr","year":"1999","journal-title":"Genes Dev"},{"issue":"16","key":"pone.0344028.ref031","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"GM Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"pone.0344028.ref032","doi-asserted-by":"crossref","unstructured":"Ahmad S, Bano N, Raza K (2025). RCSB Protein Data Bank: revolutionising drug discovery and design for over five decades. Med. Data Min. 2025;8(2):7\u201311. https:\/\/doi.org\/10.53388\/MDM202508008","DOI":"10.53388\/MDM202508008"},{"key":"pone.0344028.ref033","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"C Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"pone.0344028.ref034","volume-title":"LigPrep","author":"LLC Schr\u00f6dinger","year":"2024"},{"issue":"9","key":"pone.0344028.ref035","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1021\/acs.jcim.9b00367","article-title":"Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors","volume":"59","author":"KD Konze","year":"2019","journal-title":"J Chem Inf Model"},{"issue":"7","key":"pone.0344028.ref036","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"C Lu","year":"2021","journal-title":"J Chem Theory Comput"},{"issue":"2023","key":"pone.0344028.ref037","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1021\/acs.jctc.3c00044","article-title":"Epik: pKa and Protonation State Prediction through Machine Learning","volume":"19","author":"RC Johnston","year":"2023","journal-title":"J Chem Theory Comput"},{"key":"pone.0344028.ref038","volume-title":"Epik","author":"LLC Schr\u00f6dinger","year":"2024"},{"key":"pone.0344028.ref039","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1080\/07391102.2022.2060308","article-title":"Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an in-silico study","volume":"41","author":"S Ahmad","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0344028.ref040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-323-90608-1.00001-0","article-title":"Fundamentals of molecular modeling in drug design","volume-title":"Computer Aided Drug Design (CADD): From ligand-based methods to structure-based approaches","author":"MK Tripathi","year":"2022"},{"issue":"3","key":"pone.0344028.ref041","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"MP Jacobson","year":"2002","journal-title":"J Mol Biol"},{"issue":"2","key":"pone.0344028.ref042","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00726-012-1402-z","article-title":"A proteomic Ramachandran plot (PRplot)","volume":"44","author":"O Carugo","year":"2013","journal-title":"Amino Acids"},{"issue":"16","key":"pone.0344028.ref043","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1080\/07391102.2023.2248260","article-title":"Unveiling the multitargeted potency of Sodium Danshensu against cervical cancer: a multitargeted docking-based, structural fingerprinting and molecular dynamics simulation study","volume":"42","author":"S Alghamdi","year":"2024","journal-title":"J Biomol Struct Dyn"},{"issue":"25","key":"pone.0344028.ref044","doi-asserted-by":"crossref","first-page":"22748","DOI":"10.1074\/jbc.M212711200","article-title":"The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism","volume":"278","author":"B Kauppi","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0344028.ref045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/jm990401t","article-title":"Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase","volume":"43","author":"L Shewchuk","year":"2000","journal-title":"J Med Chem"},{"issue":"7","key":"pone.0344028.ref046","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"AK Shiau","year":"1998","journal-title":"Cell"},{"issue":"7","key":"pone.0344028.ref047","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/ct200133y","article-title":"Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values","volume":"7","author":"CR S\u00f8ndergaard","year":"2011","journal-title":"J Chem Theory Comput"},{"issue":"7","key":"pone.0344028.ref048","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"RA Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"pone.0344028.ref049","volume-title":"Glide","author":"L Schr\u00f6dinger","year":"2024"},{"key":"pone.0344028.ref050","volume-title":"Induced Fit Docking Protocol; Glide","author":"LLC Schr\u00f6dinger","year":"2024"},{"key":"pone.0344028.ref051","volume-title":"QikProp","author":"L Schr\u00f6dinger","year":"2024"},{"issue":"1","key":"pone.0344028.ref052","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/ijms25010592","article-title":"Delineated 3-1-BenCarMethInYlPro-Phosphonic Acid\u2019s Adroit Activity against Lung Cancer through Multitargeted Docking, MM\\GBSA, QM-DFT and Multiscale Simulations","volume":"25","author":"MA Hakami","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"18","key":"pone.0344028.ref053","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/qua.24481","article-title":"Jaguar: A high\u2010performance quantum chemistry software program with strengths in life and materials sciences","volume":"113","author":"AD Bochevarov","year":"2013","journal-title":"Int J of Quantum Chemistry"},{"key":"pone.0344028.ref054","volume-title":"Jaguar","author":"LLC Schr\u00f6dinger","year":"2024"},{"issue":"4","key":"pone.0344028.ref055","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1039\/C4CP04399E","article-title":"Theoretical insight into hydrogen adsorption onto graphene: a first-principles B3LYP-D3 study","volume":"17","author":"M Darvish Ganji","year":"2015","journal-title":"Phys Chem Chem Phys"},{"key":"pone.0344028.ref056","volume-title":"WaterMap User Manual","author":"LLC Schr\u00f6dinger","year":"2023"},{"issue":"9","key":"pone.0344028.ref057","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"RA Copeland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"pone.0344028.ref058","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.2174\/1568026617666170414141452","article-title":"Calculating Water Thermodynamics in the Binding Site of Proteins - Applications of WaterMap to Drug Discovery","volume":"17","author":"D Cappel","year":"2017","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"pone.0344028.ref059","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"P Csermely","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"pone.0344028.ref060","volume-title":"Desmond Molecular Dynamics System","author":"LLC Schr\u00f6dinger","year":"2024"},{"key":"pone.0344028.ref061","volume-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters, Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing","author":"KJ Bowers","year":"2006"},{"issue":"38","key":"pone.0344028.ref062","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"P Mark","year":"2001","journal-title":"J Phys Chem A"},{"issue":"1","key":"pone.0344028.ref063","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/00268977200100031","article-title":"NpT-ensemble Monte Carlo calculations for binary liquid mixtures","volume":"23","author":"I McDonald","year":"1972","journal-title":"Mol Phys"},{"issue":"1","key":"pone.0344028.ref064","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"CA Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"pone.0344028.ref065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development","volume":"25","author":"M Recanatini","year":"2005","journal-title":"Med Res Rev"},{"issue":"2","key":"pone.0344028.ref066","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"X-Y Meng","year":"2011","journal-title":"Curr Comput Aided Drug Des"},{"issue":"1","key":"pone.0344028.ref067","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"G Sliwoski","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"19","key":"pone.0344028.ref068","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"A Anighoro","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0344028.ref069","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"AS Reddy","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"pone.0344028.ref070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cbpa.2010.06.176","article-title":"Drug-target residence time: critical information for lead optimization","volume":"14","author":"H Lu","year":"2010","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"pone.0344028.ref071","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"ZA Knight","year":"2005","journal-title":"Chem Biol"},{"key":"pone.0344028.ref072","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7007-9-71","article-title":"Molecular dynamics simulations and drug discovery","volume":"9","author":"JD Durrant","year":"2011","journal-title":"BMC Biol"},{"issue":"2","key":"pone.0344028.ref073","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drudis.2016.11.001","article-title":"Molecular dynamics-driven drug discovery: leaping forward with confidence","volume":"22","author":"A Ganesan","year":"2017","journal-title":"Drug Discov Today"},{"issue":"5","key":"pone.0344028.ref074","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","article-title":"Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors","volume":"98","author":"A Kuzmanic","year":"2010","journal-title":"Biophys J"},{"issue":"1","key":"pone.0344028.ref075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/cr200107z","article-title":"Challenges for density functional theory","volume":"112","author":"AJ Cohen","year":"2012","journal-title":"Chem Rev"},{"issue":"5","key":"pone.0344028.ref076","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/cr990029p","article-title":"Conceptual density functional theory","volume":"103","author":"P Geerlings","year":"2003","journal-title":"Chem Rev"},{"issue":"3","key":"pone.0344028.ref077","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1073\/pnas.0610202104","article-title":"Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding","volume":"104","author":"T Young","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"127","key":"pone.0344028.ref078","article-title":"Intratumor heterogeneity: seeing the wood for the trees","volume":"4","author":"TA Yap","year":"2012","journal-title":"Sci Transl Med"},{"issue":"9","key":"pone.0344028.ref079","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"JB Fitzgerald","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"11","key":"pone.0344028.ref080","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"AL Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"7019","key":"pone.0344028.ref081","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nature03197","article-title":"Virtual screening of chemical libraries","volume":"432","author":"BK Shoichet","year":"2004","journal-title":"Nature"},{"issue":"20","key":"pone.0344028.ref082","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","article-title":"A critical assessment of docking programs and scoring functions","volume":"49","author":"GL Warren","year":"2006","journal-title":"J Med Chem"},{"issue":"8","key":"pone.0344028.ref083","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"I Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"pone.0344028.ref084","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"S Kalepu","year":"2015","journal-title":"Acta Pharm Sin B"},{"issue":"22","key":"pone.0344028.ref085","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology - foe or friend?","volume":"56","author":"J-U Peters","year":"2013","journal-title":"J Med Chem"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:33:57Z","timestamp":1774287237000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344028"}},"subtitle":[],"editor":[{"given":"Prashant","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344028","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}